EKR Therapeutics gets $95 million credit facility

By Sara Rosenberg

New York, March 10 - EKR Therapeutics, Inc. closed on a new $95 million senior secured credit facility, according to a news release.

GE Capital acted as the lead bank on the deal.

The facility consists of a $15 million revolver and an $80 million term loan A.

Proceeds will be used for working capital and to acquire certain cardiovascular assets, including the currently marketed Cardene and Retavase, and the development product ularitide.

EKR is a Cedar Knolls, N.J.-based specialty pharmaceutical company focused on products for the acute care setting.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.